PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS
|
|
- Ophelia Riley
- 6 years ago
- Views:
Transcription
1 8. PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS David Burger José Moltó Table 8.1a: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES NtRTI Fasting Low-fat meal High-fat meal Recommendation Zidovudine None Didanosine Fasting Stavudine None Lamivudine None Abacavir None Emtricitabine None Tenofovir None Saquinavir High-fat meal Ritonavir Meal PROTEASE INHIBITORS Saquinavir (+ Ritonavir) High-fat meal Indinavir Fasting Indinavir (+ Ritonavir) None* Fosamprenavir None Lopinavir Meal Atazanavir Meal Tipranavir Meal Darunavir Meal 491
2 NNRTIs Fasting Low-fat meal High-fat meal Recommendation Nevirapine None Delavirdine Fasting Efavirenz None Etravirine Meal Rilpivirine Meal Raltegravir None INTEGRASE INHIBITORS Elvitegravir Meal Dolutegravir None** CCR5 ANTAGONISTS Maraviroc None * Intake with food is advised because this reduces indinavir peak concentrations without influencing the AUC, this may reduce the incidence of nephrolithiasis ** Intake of dolutegravir with food is recommended in case of treatment of patients with integrase resistance 492
3 Table 8.1b: INFLUENCE OF FOOD ON ABSORPTION (AREA UNDER THE CURVE) OF ANTI-HCV AGENTS Fasting Low-fat meal High-fat meal Recommendation Ribavirin Meal Sofosbuvir Meal Simeprevir Meal Daclatasvir None Sofosbuvir+ Ledipasvir Sofosbuvir + Velpatasvir Paritaprevir+ Ritonavir+ Ombitasvir None None Meal Dasabuvir None Grazoprevir+ Elbasvir None 493
4 Table 8.2a: PHARMACOKINETIC PARAMETERS OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES F Tmax T-half Vd (L/kg) CL/F (L/hr.kg) Fu Fe Zidovudine Didanosine >95 50 Stavudine >95 50 Lamivudine >95 70 Abacavir <2 Emtricitabine >96 86 NtRTI PROTEASE INHIBITORS NNRTIs Tenofovir DF < Tenofovir AF 1 23 < Saquinavir < 2 < 5 Ritonavir < 2 < 5 Indinavir Nelfinavir < 2 < 5 Lopinavir <2 2 Atazanavir Fosamprenavir <1 Tipranavir <1 <1 Darunavir Nevirapine <5 Delavirdine <2 <5 Efavirenz <1 <1 Etravirine 3 41 <1 <1 Rilpivirine <1 <1 494
5 F Tmax T-half Vd (L/kg) CL/F (L/hr.kg) Fu Fe Raltegravir INTEGRASE INHIBITORS Elvitegravir/c Dolutegravir <1 <1 ENTRY INHIBITORS Maraviroc Enfuvirtide F: oral bioavailabiltiy; Tmax: time to maximum concentration; T-half: elimination halflife; Vd/F: apparent volume of distribution; CL/F: apparent oral clearance; Fu: fraction unbound to protein; Fe: fraction of the dose excreted unchanged in urine. 495
6 Table 8. 2b: PHARMACOKINETIC PARAMETERS OF ANTI-HCV AGENTS F Tmax T-half Vd (L/kg) CL/F (L/ hr.kg) Fu Ribavirin Sofosbuvir Simeprevir <1 <1 Daclatasvir Ledipasvir Fe Velpatasvir 3 15 <0.5 <0.4 Paritaprevir Ombitasvir Dasabuvir Grazoprevir <1.2 <1 Elbasvir <0.1 <1 F: oral bioavailabiltiy; Tmax: time to maximum concentration; T-half: elimination halflife; Vd/F: apparent volume of distribution; CL/F: apparent oral clearance; Fu: fraction unbound to protein; Fe: fraction of the dose excreted unchanged in urine. 496
7 Table 8. 3a: PLASMA DRUG CONCENTRATIONS OF ANTIRETROVIRAL AGENTS NUCLEOSIDE ANALOGUES Dose (mg) Dose interval Cmax (mg/l) Cmin (mg/l) AUC (mg/l.hr) Zidovudine 300mg < Didanosine 200mg < Didanosine < Stavudine 40mg Lamivudine 150mg Abacavir 300mg 12 3 < Emtricitabine 200mg NtRTI Tenofovir DF 245mg < Tenofovir AF 25mg Saquinavir (Fortovase) 1200mg PROTEASE INHIBITORS Saquinavir (Invirase) 1200mg Ritonavir 600mg Indinavir 800mg Fosamprenavir Lopinavir* Atazanavir Tipranavir* Darunavir*
8 NNRTIs Nevirapine Dose (mg) Dose interval Cmax (mg/l) Cmin (mg/l) AUC (mg/l.hr) 200mg Delavirdine Efavirenz 600mg Etravirine 200mg Rilpivirine 25mg Raltegravir INTEGRASE INHIBITORS Elvitegravir/c 150mg Dolutegravir 50mg ENTRY INHIBITORS Enfuvirtide 90mg Maraviroc 300mg Cmax: maximum plasma concentration (= peak); Cmin: minimum plasma concentration (= trough); AUC: area under the plasma concentration-time curve. * only data available for ritonavir-boosted regimen 498
9 Table 8. 3b: PLASMA DRUG CONCENTRATIONS OF ANTI-HCV AGENTS Dose (mg) Dose interval Cmax (mg/l) Cmin (mg/l) AUC (mg/l.hr) Ribavirin Sofosbuvir Simeprevir Daclatasvir Ledipasvir Velpatasvir Paritaprevir Ombitasvir Dasabuvir Grazoprevir Elbasvir Cmax: maximum plasma concentration (= peak); Cmin: minimum plasma concentration (= trough); AUC: area under the plasma concentration-time curve. * only data available for ritonavir-boosted regimen 499
10 Table 8. 4: PHARMACOKINETIC PARAMETERS OF HIV PROTEASE INHIBITORS WHEN TAKEN IN DUAL PI OR LOW-DOSE RITONAVIR BOOSTED REGIMENS Saquinavir Saquinavir Dose 1000mg Other PI + dose RTV RTV 100mg Saquinavir 1600mg RTV 100mg Ritonavir Indinavir Ritonavir Indinavir Indinavir Indinavir 800mg 800mg SQV RTV IDV RTV 100mg RTV 200mg RTV 100mg Fosamprenavir 700mg RTV 100mg Fosamprenavir 1 RTV 200mg Atazanavir 300mg RTV 100mg Cmax (mg/l) Cmin (mg/l) AUC (mg/l.hr) Cmax: maximum plasma concentration (= peak); Cmin: minimum plasma concentration (= trough); AUC: area under the plasma concentration-time curve (for a given dose interval). 500
11 Table 8. 5a: DOSE ADJUSTMENTS OF ANTIRETROVIRAL AGENTS FOR HEPATIC OR RENAL DYSFUNCTION NUCLEOSIDE ANALOGUES NtRTI PROTEASE INHIBITORS Zidovudine Normal dose 300mg Hepatic dysfunction Renal dysfunction < 10 removed by dialysis 300mg Normal Normal 300mg Yes Didanosine 1 Normal Normal 200mg 100mg Yes Stavudine 40mg Normal Normal 20mg 20mg Yes Lamivudine Abacavir Emtricitabine Tenofovir DF 150mg 300mg 200mg 245mg Normal Normal mg 25mg Yes 200mg Normal Normal Normal Yes Normal Normal 200mg q2-3 days Normal Normal 245mg q2-4days Tenofovir AF 25mg Normal Normal Normal Saquinavir 1200mg TID 200mg q4 days 245mg q7days Contraindication Yes Yes Yes Normal Normal Normal Normal No Ritonavir 600mg Normal Normal Normal Normal No Indinavir 2 800mg TID 600mg TID Normal Normal Normal Yes Nelfinavir Lopinavir Fosamprenavir Atazanavir Tipranavir 1250mg 1 500mg Normal Normal Normal Normal No - Normal Normal Normal No See 4 Normal Normal Normal No 300mg Normal Normal Normal No Normal Normal Normal Normal No Darunavir 600mg Normal Normal Normal Normal No 501
12 NNRTIs INTEGRASE INHIBITORS Nevirapine Delavirdine Efavirenz Etravirine Rilpivirine Raltegravir Normal dose TID 600mg 200mg BD 25mg BD Hepatic dysfunction Elvitegravir/c 125mg Normal Normal Renal dysfunction < 10 removed by dialysis Normal Normal Normal Normal Yes Normal Normal Normal Normal No Normal Normal Normal Normal No Normal Normal Normal Normal No Normal Normal Normal Normal No Normal Normal Normal Normal No Not possible Not possible Not possible Dolutegravir 50mg Normal Normal Normal 5 Normal 5 No ENTRY INHIBITORS Enfuvirtide Maraviroc 90mg 300mg BD Normal Normal Normal Unknown No Unknown See 6 See 6 See 6 Yes? 1 Didanosine chewable tablet formulation contains cations (Na, Mg) that can accumulate in patients with significant renal impairment 2 Renal excretion of indinavir increases up to 50% when combined with ritonavir ; consider empirical dosage reduction under the guidance of therapeutic drug monitoring 3 There is not much experience with dosing of antiretroviral agents in hepatic dysfunction; caution is needed; the recommendations are based on patients with mild to moderate hepatic dysfunction; patients with severe hepatic dysfunction should be treated case by case 4 Dosing of fosamprenavir is dependent on Child-Pugh score: 5-6: fosamprenavir 700mg BD + ritonavir 100mg ; 7-9: fosamprenavir 450mg BD + ritonavir 100mg ; 10-15: fosamprenavir 300mg BD + ritonavir 100mg 5 Dolutegravir AUC was decreased by 40% in patients with creatinine clearance <30 ; this is not a concern in patients without integrase resistance but might result in loss of therapeutic effect in patients with integrase resistance. 6 If creatinine clearance: < 80 ml/min: when maraviroc is administered with tipranavir/r: no dose adjustment required. When maraviroc is administered with fosamprenavir/rtv: 150mg. If it is administered with lopinavir/rtv, darunavir/rtv, saquinavir/rtv or atazanavir/rtv: 150mg 502
13 Table 8. 5b: DOSE ADJUSTMENTS OF ANTI-HCV AGENTS FOR HEPATIC OR RENAL DYSFUNCTION Normal dose Hepatic dysfunction Ribavirin Normal mg/ day Renal dysfunction / on alternate days < mg Sofosbuvir 400 Normal Normal Normal Contraindicated 3 removed by dialysis Simeprevir 150 Normal 2 Normal Normal Normal No No Yes Daclatasvir 60 Normal Normal Normal Normal No Ledipasvir 100 Normal Normal Normal Normal No Velpatasvir 100 Normal Normal Normal Normal No Paritaprevir 50 Normal 2 Normal Normal Normal Unknown Ombitasvir 150 Normal 2 Normal Normal Normal Unknown Dasabuvir 250 Normal 2 Normal Normal Normal Unknown Grazoprevir 100 Normal 2 Normal Normal Normal No Elbasvir 50 Normal 2 Normal Normal Normal No 1 TDM of ribavirin is recommended 3 SOF is contra-indicated in patients with CrCL < 30 ; if given to these patients the normal dose should be administered PEDIATRIC DOSES OF ANTIRETROVIRAL AGENTS see: 503
14 THERAPEUTIC DRUG MONITORING (TDM) FOR ANTIRETROVIRAL AGENTS: STATUS AND PERSPECTIVES Current highly active antiretroviral therapies (HAART) result in a significant suppression of HIV replication and in a marked improvement in clinical outcomes. However, the efficacy of antiretroviral treatment may be impaired by several factors, including poor adherence on the part of the patients, the presence of treatment related side effects, selection of antiretroviral-resistant HIV viral strains, and suboptimal concentrations of antiretroviral agents. A growing interest has been generated in recent years regarding the importance of concentrations of antiretroviral agents in plasma, and the role that inadequate drug concentrations may play in treatment failure or drug resistance. Rationale for the Use of TDM of Antiretroviral Therapy Dose-response relationship in which higher doses of the drug are related to a more durable viral suppression exists for many antiretroviral agents Failure to maintain adequate concentrations will eventually allow the development of viral resistance, thereby decreasing the probability of response of current and subsequent therapies. On the other hand, excessively high drug concentrations may contribute, at least in part, to the appearance of antiretroviral therapy-related adverse events. However, the current practice of administering a fixed dosage of antiretroviral agents for all patients produces different concentrations of drugs (interindividual variability) Therapeutic drug monitoring (TDM) consists of individualizing dosages with the aim to maintain drug concentrations within a preestablished therapeutic range. The usefulness of this approach to maximize the efficacy while minimizing toxicity of several drugs has been proved in different therapeutic areas, such as antiarrhytmics, anticonvulsants or aminoglycoside antibiotics. Likewise, since HIV suppression seems to be so dependent on adequate drug concentrations, the use of TDM in this scenario would be highly desirable. However, the wide therapeutic range of the new antiretrovirals in current use together with the lack of large-scale prospective studies showing that TDM is a useful tool to improve the management of all HIV-infected subjects who start to take an ARV regimen constitute the main limiting factors for performing TDM in the HIV field. Current Status and Perspectives Consider TDM for specific indications patients with significan drug-drug or drug-food interactions patients with changes in pathophysiological state that may impair gastrointestinal, hepatic or renal function 504
15 in treatment-experienced patients who may have viral isolates with reduced susceptibility to HAART use of alternative dosing regimens whose safety and efficacy have not been established in clinical trials concentration dependent toxicities lack of expected virological response in a treatment naïve person monitoring adherence pregnant or pediatric patients 2. Provide a plasma sample for TDM with at least the following information: patient identifiers indication for TDM dose and frequency of the drug time of last intake of medication and time sample was taken co-medications 3. Take a blood sample noting the correct time after drug intake This requires the patient to have reached the steady state, usually 2 weeks after starting the drug. 4. Use trough samples to monitor virological efficacy and peak samples for toxicity management. Trough samples need to be measured 8h for TID, 12 hours for, and 24 hours for a drug. 5. Undertake TDM for those drugs where a concentration range has been defined (Table 1) 6. Send samples for TDM to a laboratory that you know participates in both internal and external QC programme 7. Monitoring drug concentrations of nucleoside reverse transcriptase inhibitors (NRTIs) NRTIs are metabolized intracellularly and therefore plasma concentrations may not correlate with levels of active intracellular triphosphate which determined the efficacy of the drug. Monitoring plasma concentrations of NRTIs might be useful for the evaluation and management of a drug-drug interaction that affected the plasma concentrations of the NRTI. 8. Make sure that the active metabolite of the drug you are monitoring is being measured, where appropriate. Some drugs have a metabolite component that is measurable and affects the activity of the drug. At present, nelfinavir is the only PI that has a measurable and active metabolite (M8). 9. Only perform TDM as a part of integrated approach in your overall clinical management. TDM can be an extremely valuable tool assisting you in your clinical management of patients, but it is only helpful when combined with other equally important treatment considerations. 10. When performing TDM, take into consideration the intrapatient variability observed with drug concentrations. 505
16 REFERENCES Activity for an HIV drug across the population may be extremely variable and drug concentration within the therapeutic range does not itsef guarantee a therapeutic concentration at any given time. Levels of systemic exposure to PIs and NNRTIs correlate with their efficacy and some of their adverse effects. Therefore, adjusting PIs and NNRTIs concentrations within a therapeutic window may be of benefit. TDM has potential for patients who are beginning therapy with any PI or NNRTI or who are changing regimens, regardless of treatment history or pharmacoenhancement with ritonavir, to ensure appropriate drug concentrations and to exclude absorption or metabolic problems and unexpected drug-drug interactions 1. Back D, et al. AIDS 2002;S5-S Murphy R. AIDS Rev 1999;1: Drusano GL, et al. J Infect Dis 1998;78: Reijers MH, et al. AIDS 2000;14: Burger DM, et al. Antivir Ther 1998;3: Dieleman JP, et al. AIDS 1999;13: Gieschke R, et al. Clin Pharmacokinet 1999;37: Burger D, et al. Ther Monit 2003;25: Sadler BM, et al. Antimicrob Agents Chemother 2001;45: Masquelier B, et al. Antimicrob Agents Chemother 2002;46: Marzolini C, et al. AIDS 2001;15: Veldkamp AL, et al. AIDS 2001;15: Havlir D, et al. J Infect Dis 1995;171: Gonzalez de Requena D, et al. 12th CROI. Boston, [abstract 645] 15. Torti C, et al. AIDS Patient Care and STDs 2004;18: de Maat MM, et al. Ther Monit 2003;25: Moltó J, et al. Br J Clin Pharmacol 2006;62: la Porte C, et al. Reviews in Antiviral Therapy 2006; 3:
Antiretroviral Dosing in Renal Impairment
Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis
More informationTORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION
TGH - ambulatory rotation page 1 of 5 TORONTO GENERAL HOSPITAL HIV AMBULATORY CARE ROTATION SITE: Immunodeficiency Clinic, Toronto General Hospital, University Health Network Location: 13 th floor, Norman
More informationHIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily
HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/
More informationTHE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work
THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More informationDistribution and Effectiveness of Antiretrovirals in the Central Nervous System
Distribution and Effectiveness of Antiretrovirals in the Central Nervous System Scott Letendre, MD Associate Professor of Medicine HIV Neurobehavioral Research Center and Antiviral Research Center University
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationPOST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV
POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none
More informationFluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids
Supportive therapy Summary of interactions Table 1. Summary of potential interactions between antiretroviral agents and supportive therapy Interactions with enzyme inhibitors (protease inhibitors and elvitegravir/cobicistat)
More informationHIV Drugs and the HIV Lifecycle
HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's
More informationTB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationTB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
More informationHIV associated CNS disease in the era of HAART
HIV associated CNS disease in the era of HAART CSF/CNS penetration and efficacy Acknowledgements Peter Portegies Department of Neurology, AMC Mark van der Valk Department of Internal Medicine/Infectious
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationHIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV
HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV Shibani S. Mukerji MD, PhD Massachusetts General Hospital, Division of Immunologic, Inflammatory and Infectious Neurological Diseases Dana-Farber
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationMedication Errors Focus on the HIV-Infected Patient
Medication Errors Focus on the HIV-Infected Patient Nimish Patel, Pharm.D., Ph.D., AAHIVP Associate Professor Albany College of Pharmacy & Health Sciences I do not have any conflict of interest in relation
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationCentral Nervous System Penetration of ARVs: Does it Matter?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Central Nervous System Penetration of ARVs: Does it Matter? Christina M. Marra, MD Neurology and Medicine (Infectious Diseases) University of Washington 15
More informationWOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION
WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /
More informationIndustry Data Request
Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts,
More informationSection 6: Treatment of Hepatitis C virus (HCV)
Section 6: Treatment of Hepatitis C virus (HCV) Dr. Niklas Luhmann (Médecins du Monde) Training Hepatitis C and HR for PWUD, 9 th -13 th May 2016, Hanoi, Vietnam Learning objective of the session: understanding
More informationSlide 1 Will DAA drug interactions matter in the future? David Back. David Back University of Liverpool UK. University of Liverpool June 2015
Slide 1 Will DAA drug interactions matter in the future? David Back University of Liverpool UK David Back University of Liverpool June 2015 Disclosures Honoraria received for Advisory Boards, lectures
More informationDaclatasvir (Daklinza ) Drug Interactions with HIV Medications
Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationClinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in treatment of HIV positive adults and adolescents 1 Clinical Commissioning Policy: Use of cobicistat (Tybost ) as a booster in
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationPharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005
Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers
More informationSelected Issues in HIV Clinical Trials
Selected Issues in HIV Clinical Trials Judith S. Currier, M.D., MSc Professor of Medicine Division of Infectious Diseases University of California, Los Angeles Issues Evolving Global and Domestic Epidemic
More informationIndustry Request Integrase Inhibitors
Industry Request Integrase Inhibitors The objective of this request is to describe and understand the temporal changes in the prescribing practices of Integrese Inibitors (II) in AHOD cohort between 1/1/
More informationANTIRETROVIRAL TREATMENTS (Part 1of
CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after
More informationHIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego
HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD Professor of Medicine University of California, San Diego Disclosures Grant/research support Abbvie Gilead Sciences
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationSeparate clinical trials for HIV- HCV coinfected patients are NOT a necessity. Patrick Ingiliz, Berlin
Separate clinical trials for HIV- HCV coinfected patients are NOT a necessity Patrick Ingiliz, Berlin Back in the days when HCV genotype 1 was the problem SVR (%) 100 90 80 70 60 50 40 30 20 10 0 35% PRESCO
More informationPhysiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters
Physiologically-Based Simulation of Daclatasvir Pharmacokinetics With Antiretroviral Inducers and Inhibitors of Cytochrome P450 and Drug Transporters Qi Wang, Wenying Li, Ming Zheng, Timothy Eley, Frank
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationHIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego
Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego HIV DISEASE! Neuromedical Neurobehavioral! HIV Neurobehavioral Disturbances HIV Associated Neurocognitive
More information104 MMWR December 17, 2004
104 MMWR December 17, 2004 TABLE 8. Substantial pharmacokinetic drug-drug interactions for drugs used in the treatment of opportunistic Drugs Interacting with Mechanism/effects Recommendations Acyclovir
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)
More informationActualización y Futuro en VIH
Actualización y Futuro en VIH Dr. Santiago Moreno Servicio de Enfermedades Infecciosas Hospital U. Ramón y Cajal. Universidad de Alcalá. IRYCIS. Madrid Agenda Control of the HIV-epidemic Coinfections Antiretroviral
More informationPharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP
Pharmacologic Considerations of HCV Treatment Autumn Zuckerman, PharmD, BCPS, AAHIVP Objectives Review pharmacokinetic properties of currently utilized Hepatitis C medications Review drug interactions
More informationNorthwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care
Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University
More informationThe Hospitalized HIV+ Patient
The Hospitalized HIV+ Patient Danny Toub MD dannyt@srheathcenters.org October 8, 2012 Santa Rosa Family Medicine Residency List 3 ways of risk-stratifying known or suspected HIV+ inpatients Perform differential
More informationHIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship
HIV basics Katya Calvo Medical Director of Antimicrobial Stewardship Learning Objectives 1. Review of HIV epidemiology worldwide and locally 2. Review of recommendations on whom to screen 3. Work up of
More informationTreatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV)
Treatment of respiratory virus infection Influenza A & B Respiratory Syncytial Virus (RSV) Amantadine and Rimantadine Use is limited to Influenza A infection. Very effective in preventing infection if
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationWhen to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc
When to Start ART Exact CD4 count at which to initiate therapy not known, but evidence points to starting at higher counts Current recommendation: ART for all patients with CD4 count of
More informationClass Review: HIV Antiretroviral Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThis graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts
1 2 This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts decreased. This period of acute infection or serocnversion
More informationToo small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants
Too small, too soon: antiretroviral prophylaxis and treatment in preterm and low birth weight infants Mark Mirochnick, MD Boston University School of Medicine, Boston, MA, USA Full Term Full Term 34 wks
More informationARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting
ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting Dr. Andrew D Kambugu, FRCP (UK) Infectious Diseases Institute, Makerere University Outline of Discussion Key Definitions
More informationSelecting an Initial Antiretroviral Therapy (ART) Regimen
Selecting an Initial Antiretroviral Therapy (ART) Regimen An HIV Diagnosis is a Call to Action In support of the NYSDOH AIDS Institute s January 2018 call to action for patients newly diagnosed with HIV,
More informationHIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014
Objectives HIV Update 2014 Jay Sizemore, MD, MPH Medical Director Chattanooga CARES Assistant Professor UTCOM Chattanooga 2October 2014 Review HIV epidemiology and screening/testing guidelines Discuss
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationNON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM
NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION Jason E. Vercher, PA-C, AAHIVM Disclosures No disclosures to report Learning Objectives q Identify Individuals who would benefit from non-occupational
More informationRisk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf
Risk of HIV-1 low level viremia to treatment failure in the AREVIR-RESINA cohort in Germany Nadine Lübke Düsseldorf FDA Approval of antiretroviral drugs 1980-84 1985-89 1990-94 1995-99 2000-04 2005-09
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationPharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2008.03220.x Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women Matthieu Roustit, 1,2 Malik Jlaiel, 1
More informationThe ART of Managing Drug-Drug Interactions in Patients with HIV
The ART of Managing Drug-Drug Interactions in Patients with HIV Bradley L. Smith, Pharm.D. smith.bradley1@mayo.edu Pharmacy Grand Rounds December 19, 2017 2017 MFMER slide-1 Presentation Objectives Describe
More informationTHERAPEUTIC DRUG MONITORING (TDM) Table 2. Dose Adjustment. Patient Drug (mg) Symptoms C trough -fold increase compared to MEC WT
1 The Sixth International Congress on Drug Therapy in HIV Infection took place in Glasgow, UK, on November 17-21, 2002. Pharmacological aspects of antiretroviral therapy were covered in both oral and poster
More informationClinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents
Clinical Commissioning Policy: Use of cobicistat as a booster in treatment of HIV positive adults and adolescents Reference: NHS England F03/P/b NHS England INFORMATION READER BOX Directorate Medical Commissioning
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationDidactic Series. HIV Drug-Drug Interactions: OTC and non-prescription medications. Kirsten B. Balano, PharmD UCSF School of Pharmacy February 26, 2015
Didactic Series HIV Drug-Drug Interactions: OTC and non-prescription medications Kirsten B. Balano, PharmD UCSF School of Pharmacy February 26, 2015 ACCREDITATION STATEMENT: University of California, San
More informationHIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
Review Article HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals Donald P. Rice Jr.* 1, John J. Faragon 2, Sarah Banks 3 and Lisa M. Chirch 1 1 Division of Infectious Diseases,
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationINFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL
Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute
ADAP Monitoring Provider Prescribing Patterns Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute WEBINAR ETIQUETTE All questions or comments can be shared either via the
More informationHIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options
STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living
More informationAn HIV Update Jan Clark, PharmD Specialty Practice Pharmacist
An HIV Update - 2019 Jan Clark, PharmD Specialty Practice Pharmacist 2 The goal of this program is to provide a review and update of HIV care and to provide a forum for discussing the current local and
More informationMonographs on ARV and hepatitis medicines in The International Pharmacopoeia
Monographs on ARV and hepatitis medicines in The International Pharmacopoeia Technologies, Standards and Norms 1 The International Pharmacopoeia contains analytical methods and specifications for active
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationDr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.
BHIVA AUTUMN CONFERENCE 2010 Including CHIVA Parallel Sessions Dr Alan Winston Imperial College Healthcare NHS Trust London 7-8 October 2010, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More information5/2/2016. Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois. Learning Objectives
Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection Andrew I. Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois FORMATTED: 05/02/2016 Chicago,
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationCOMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL
COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine
More informationAntiretroviral Therapy
Antiretroviral Therapy Scott M. Hammer, M.D. 1986 1990 ZDV monorx 1990 1995 Alternative NRTI monorx Combination NRTI Rx Introduction of NNRTI s Antiretroviral resistance Pathogenetic concepts Evolution
More informationANTIRETROVIRAL THERAPY
ANTIRETROVIRAL THERAPY Editor s Note: Section III: Deciding When to Initiate ART is currently under revision due to recent data in favor of further expanding indications for antiretroviral therapy. What
More informationHepatitis C: Module Options for genotype 1a and 1b pros and cons
Drug Regimen HCV genotype Pros Cons Sofosbuvir 400mg + ledipasvir 90mg, orally, Sofosbuvir 400mg, orally, + daclatasvir 60mg, orally Elbasvir 50mg + grazoprevir 100mg, orally Once- single pill regimen.
More informationApproach for the Newly Diagnosed HIV Positive Patient
Approach for the Newly Diagnosed HIV Positive Patient Jason E. Farley, PhD, MPH, ANP-BC, FAAN, AACRN Associate Professor & NP, Johns Hopkins University School of Nursing & Medicine Director, AETC Adult-Gerontology
More informationWOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM
WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationHuman Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications
Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV
More informationEffects of cobicistat on tenofovir exposure and its long-term tolerability: is it time to rethink at TAF trials?
Effects of cobicistat on tenofovir exposure and its long-term tolerability: is it time to rethink at TAF trials? Sara Baldelli 1, Andrea Giacomelli 2, Davide Minisci 2, Cristina Mazzali 3, Laura Milazzo
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationHIV Management Update 2015
9/30/15 HIV Management Update 2015 Larry Pineda, PharmD, PhC, BCPS Visiting Assistant Professor Pharmacy Practice and Administrative Science ljpineda@salud.unm.edu Pharmacist Learning Objectives Describe
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 37 1. NAME OF THE MEDICINAL PRODUCT Tablets* 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 600 mg efavirenz, 200 mg emtricitabine
More informationFriday afternoon Programme
Friday afternoon Programme Pharmacology and TDM Dr Marta Boffito Consultant Physician, C&W Resistance to new anti-retrovirals Dr Steve Taylor Consultant Physician, Birmingham HIVPA Annual Conference 2008
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More information